Table 3.
Overview of stereotactic body radiotherapy for lung cancer adrenal metastases
| Trial | Patients /lesions | Median follow-up (months) | NSCLC/ SCLC | Metachronous/ Synchronous | Total dose/ fractions | Median BED10 (Gy) | Median PTV (cc) | LC | OS |
| Oshiro 28 | 19/19 | 10.1 | 14/5 | 13/6 | 30-60/1-27 | 48–120 | GTV 14.1 (0.52–113) | 79% | 1-y 56% 2-y 33% |
| Holy 29 | 13 | 12 | 13/0 | - | 20-40/3-8 | 22.5–72 | 176 | 1-y 77% | 1-y 66.7% |
| Guoiou 30 | 9/11 | 7.3 | 4/5 | 6/5 | 20–37.5/5 | 37.5 | 306.62 | 1-y 44% 2-y 44% | 1-y 52% 2-y 13% |
| Gamsiz 31 | 15/17 | 16 | 15/0 | - | 30/3 | 60 | 57.4 | 1-y 86.7% | 1-y 33.3% |
| Celik 32 | 15/15 | 24 | 15/0 | 8/7 | 42/6 | 71.4 | 74.4 | 1-y 60% 2-y 46.6% | 1-y 93.3% 2-y 66.6% |
| Zhao 33 | 30/32 | 10.7 | 25/5 | - | Median 44.4/5 | 85.5 | GTV 23.9 (2.5–115.3) | 1-y 96.9% 2-y 72.7% | 1-y 58.1% 2-y 54% |
| Our trial All cases | 37/38 | 10.5 | 27/10 | 23/14 | 30-50/5 | 48 | 43.5 | 1-y 63.5% 2-y 54.4% | 1-y 53% 2-y 41.1% |
| Lower dose | 26 | 12 | 19/8 | 17/10 | 30-35/5 | 48–59.5 | 49 | 1-y 54.1% 2-y 45% | 1-y 54% 2-y 40% |
| Higher dose | 11 | 8 | 9/2 | 7/4 | 40-50/5 | 72–100 | 33.5 | 1-y 100% 2-y 100% | 1-y 53% 2-y 53% |
BED, biologically effective dose; NSCLC, non-small-cell lung cancer; PTV, planning target volume; SCLC, small-cell lung cancer.